SK284359B6 - Stabilizovaná forma karbamátu, farmaceutický prostriedok s jej obsahom a spôsob jej prípravy - Google Patents

Stabilizovaná forma karbamátu, farmaceutický prostriedok s jej obsahom a spôsob jej prípravy Download PDF

Info

Publication number
SK284359B6
SK284359B6 SK109-98A SK10998A SK284359B6 SK 284359 B6 SK284359 B6 SK 284359B6 SK 10998 A SK10998 A SK 10998A SK 284359 B6 SK284359 B6 SK 284359B6
Authority
SK
Slovakia
Prior art keywords
compound
formula
pharmaceutically acceptable
hydrate
acceptable salt
Prior art date
Application number
SK109-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK10998A3 (en
Inventor
Jeffrey A. Zimmerman
John M. Williams
Paul A. Bergquist
Lisa M. Dimichele
David C. Dubost
Michael J. Kaufman
Daniel R. Sidler
William A. Hunke
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284359(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612668.5A external-priority patent/GB9612668D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of SK10998A3 publication Critical patent/SK10998A3/sk
Publication of SK284359B6 publication Critical patent/SK284359B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/887—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a hetero atom or a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK109-98A 1996-05-28 1997-05-23 Stabilizovaná forma karbamátu, farmaceutický prostriedok s jej obsahom a spôsob jej prípravy SK284359B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1851896P 1996-05-28 1996-05-28
GBGB9612668.5A GB9612668D0 (en) 1996-06-18 1996-06-18 Carbapenem antibiotic composition and method of preparation
PCT/US1997/008831 WO1997045430A1 (en) 1996-05-28 1997-05-23 Carbapenem antibiotic, composition and method of preparation

Publications (2)

Publication Number Publication Date
SK10998A3 SK10998A3 (en) 1998-08-05
SK284359B6 true SK284359B6 (sk) 2005-02-04

Family

ID=26309530

Family Applications (1)

Application Number Title Priority Date Filing Date
SK109-98A SK284359B6 (sk) 1996-05-28 1997-05-23 Stabilizovaná forma karbamátu, farmaceutický prostriedok s jej obsahom a spôsob jej prípravy

Country Status (34)

Country Link
EP (1) EP0863901B1 (zh)
JP (2) JPH11509871A (zh)
KR (2) KR100403497B1 (zh)
CN (1) CN1067074C (zh)
AT (1) ATE252584T1 (zh)
AU (1) AU710102B2 (zh)
BG (1) BG63821B1 (zh)
CA (1) CA2227994C (zh)
CO (1) CO4940412A1 (zh)
CY (1) CY2437B1 (zh)
CZ (1) CZ296381B6 (zh)
DE (1) DE69725696T2 (zh)
DK (1) DK0863901T3 (zh)
DZ (1) DZ2242A1 (zh)
EA (1) EA000534B1 (zh)
EE (1) EE04678B1 (zh)
ES (1) ES2208907T3 (zh)
HK (1) HK1016176A1 (zh)
HR (1) HRP970281B1 (zh)
HU (1) HU229426B1 (zh)
ID (1) ID16974A (zh)
IL (1) IL123078A (zh)
IS (1) IS2353B (zh)
MX (1) MX9800808A (zh)
NO (1) NO323815B1 (zh)
NZ (1) NZ329649A (zh)
PL (1) PL188917B1 (zh)
PT (1) PT863901E (zh)
RS (1) RS49583B (zh)
SI (1) SI0863901T1 (zh)
SK (1) SK284359B6 (zh)
TR (1) TR199800146T1 (zh)
TW (1) TW434014B (zh)
WO (1) WO1997045430A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000508343A (ja) * 1996-10-28 2000-07-04 メルク エンド カンパニー インコーポレーテッド 安定化されたカルバペネム抗生物質組成物及びその製造方法
PT991651E (pt) * 1997-06-16 2004-03-31 Merck & Co Inc Intermediarios de carbapenem estabilizados e uso sintetico
US6180783B1 (en) * 1997-06-16 2001-01-30 Merck & Co., Inc. Stabilized carbapenem intermediates and improved process for carbapenem synthesis
US6504027B1 (en) 1998-03-02 2003-01-07 Merck & Co., Inc. Decarboxylation process for synthesizing carbapenem antibiotics
ES2234689T3 (es) * 1999-10-29 2005-07-01 MERCK & CO., INC. Procedimiento de preparacion de composiciones de antibioticos a base de carbapenemo.
AR035728A1 (es) 2001-01-16 2004-07-07 Merck & Co Inc Proceso perfeccionado para la sintesis de carbapenem
CN101357918B (zh) * 2007-06-22 2011-05-18 山东轩竹医药科技有限公司 含有异硫脲基巯基吡咯烷的培南衍生物
CN101367815B (zh) * 2007-06-28 2012-07-04 山东轩竹医药科技有限公司 六元环甲酰胺取代的巯基吡咯烷碳青霉烯化合物
EP2229944A1 (en) * 2007-12-12 2010-09-22 Dainippon Sumitomo Pharma Co., Ltd. Preparation composition
CN101550138B (zh) * 2008-04-03 2011-05-18 山东轩竹医药科技有限公司 巯基氮杂环烷酰胺醇取代的培南衍生物
WO2009150630A2 (en) * 2008-06-11 2009-12-17 Ranbaxy Laboratories Limited Process for preparing a carbapenem antibiotic composition
EP2415758B1 (en) 2009-03-31 2017-03-01 Mitsubishi Materials Electronic Chemicals Co., Ltd. Fluorine-containing n-alkyl sulfonyl imide compound, manufacturing method therefor, and method of manufacturing an ionic compound
WO2010151574A2 (en) 2009-06-25 2010-12-29 Shell Oil Company Water injection systems and methods
WO2012047832A2 (en) 2010-10-07 2012-04-12 Shell Oil Company Process for the production of alcohols from biomass
PL2635712T3 (pl) 2010-11-05 2014-12-31 Shell Int Research Obróbka biomasy do wytworzenia materiałów użytecznych do biopaliw
WO2012088108A1 (en) 2010-12-20 2012-06-28 Shell Oil Company Process for the production of alcohols from biomass
WO2013090526A1 (en) 2011-12-15 2013-06-20 Shell Oil Company Method of treating byproducts from ethanol production
BR112014028024A2 (pt) 2012-05-17 2017-07-25 Shell Int Research método para processar um material de biomassa.
CN103860485A (zh) * 2012-12-18 2014-06-18 深圳市海滨制药有限公司 一种厄他培南钠冻干制剂及其制备方法
US20150299739A1 (en) 2014-04-17 2015-10-22 Shell Oil Company Processes for producing fermentation products
CN106536495A (zh) 2014-08-14 2017-03-22 国际壳牌研究有限公司 从生物质制备糠醛的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES525492A0 (es) * 1982-09-10 1985-02-01 Glaxo Group Ltd Un procedimiento para la produccion de un recipiente hermeticamente cerrado que contiene al menos un antibiotico de beta-lactama.
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
CA2091309A1 (en) * 1992-03-26 1993-09-27 Frederic H. Jung Antibiotic compounds

Also Published As

Publication number Publication date
NO980380L (no) 1998-03-16
EE04678B1 (et) 2006-08-15
PL188917B1 (pl) 2005-05-31
DE69725696D1 (de) 2003-11-27
DK0863901T3 (da) 2004-02-16
MX9800808A (es) 1998-04-30
PL324746A1 (en) 1998-06-08
TR199800146T1 (xx) 1998-06-22
CO4940412A1 (es) 2000-07-24
EP0863901A1 (en) 1998-09-16
EE9800022A (et) 1998-08-17
ATE252584T1 (de) 2003-11-15
EA199800180A1 (ru) 1998-08-27
BG102273A (bg) 1998-09-30
HK1016176A1 (en) 1999-10-29
CN1198162A (zh) 1998-11-04
YU4198A (sh) 1998-12-23
CA2227994A1 (en) 1997-12-04
CA2227994C (en) 2002-06-25
ES2208907T3 (es) 2004-06-16
TW434014B (en) 2001-05-16
NZ329649A (en) 1998-11-25
KR100403497B1 (ko) 2003-10-30
CZ296381B6 (cs) 2006-03-15
HUP9901567A2 (hu) 1999-09-28
JP5255983B2 (ja) 2013-08-07
IL123078A0 (en) 1998-09-24
BG63821B1 (bg) 2003-02-28
DE69725696T2 (de) 2004-07-29
ID16974A (id) 1997-11-27
RS49583B (sr) 2007-04-10
IS4663A (is) 1998-01-27
JP2009084284A (ja) 2009-04-23
CY2437B1 (en) 2004-11-12
HRP970281A2 (en) 1998-06-30
IL123078A (en) 2002-03-10
KR100344479B1 (ko) 2002-10-31
DZ2242A1 (fr) 2002-12-18
AU3077597A (en) 1998-01-05
AU710102B2 (en) 1999-09-16
CZ25398A3 (cs) 1998-07-15
CN1067074C (zh) 2001-06-13
EA000534B1 (ru) 1999-10-28
NO323815B1 (no) 2007-07-09
SI0863901T1 (en) 2004-04-30
KR19990036052A (zh) 1999-05-25
NO980380D0 (no) 1998-01-28
HUP9901567A3 (en) 2000-03-28
HRP970281B1 (en) 2002-04-30
EP0863901B1 (en) 2003-10-22
IS2353B (is) 2008-04-15
SK10998A3 (en) 1998-08-05
PT863901E (pt) 2004-02-27
WO1997045430A1 (en) 1997-12-04
JPH11509871A (ja) 1999-08-31
HU229426B1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
JP5255983B2 (ja) カルバペネム系抗生物質、組成物及び調製方法
US5952323A (en) Carbapenem antibiotic
EP1207881B1 (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
CA1043261A (en) Cephalosporin-type antibiotic composition
US6297231B1 (en) Stabilized carbapenem antibiotic compositions and method of making
EP0178911B1 (en) Composition containing a penem or carbapenem antibiotic
AU725298B2 (en) Stabilized carbapenem antibiotic compositions and method of making
KR930001830B1 (ko) 항균성 동결건조 제제
EP1326608B1 (en) Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers
BR9702231B1 (pt) composição farmacêutica, composto, e, processo para estabilizar um carbapenem
JPH08231398A (ja) 凍結乾燥製剤
GB2369358A (en) Oxapenems and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20100203

PC4A Assignment and transfer of rights

Owner name: SCHERING CORPORATION, KENILWORTH, NEW JERSEY, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20121122

TC4A Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20121122

MK4A Expiry of patent

Expiry date: 20170523